Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1
Antibiotic Selection00:57

Antibiotic Selection

52.4K
Overview
52.4K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.7K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renal Mucosa-Associated Lymphoid Tissue Lymphoma Mimicking Autoimmune Pancreatitis: A Diagnostic Challenge.

ACG case reports journal·2026
Same author

African American Dementia Caregiver Strategies Inventory: Initial descriptive and psychometric evaluation.

Rehabilitation psychology·2026
Same author

Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin Structure Infections.

Open forum infectious diseases·2026
Same author

A straight shot? The use of the right renal artery as inflow for hepatic arterial reconstruction.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same author

<i>Salmonella</i> Infections: Global Trends and Emerging Challenges.

Microorganisms·2026
Same author

Evolution of liver transplant systems.

American journal of surgery·2026

Related Experiment Video

Updated: Jun 9, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.6K

Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs.

Mayurika Ghosh, Dmitri Iarikov, Xiaojing Karen Qi

    Emerging Infectious Diseases
    |October 24, 2024
    PubMed
    Summary

    The US Food and Drug Administration (FDA) is exploring flexible clinical trial programs for new antibacterial drugs. This approach addresses challenges in developing treatments for resistant bacterial infections, particularly those targeting specific pathogens.

    Keywords:
    US Food and Drug AdministrationUnited Statesantibacterial drug developmentantimicrobial resistancebacteriacarbapenem-resistant Acinetobacter baumannii-calcoaceticus complexdurlobactamsulbactamunmet medical need

    More Related Videos

    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
    11:15

    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

    Published on: July 24, 2021

    4.5K
    Antibiotic Dereplication Using the Antibiotic Resistance Platform
    10:49

    Antibiotic Dereplication Using the Antibiotic Resistance Platform

    Published on: October 17, 2019

    10.7K

    Related Experiment Videos

    Last Updated: Jun 9, 2025

    Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
    07:50

    Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

    Published on: October 25, 2024

    1.6K
    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
    11:15

    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

    Published on: July 24, 2021

    4.5K
    Antibiotic Dereplication Using the Antibiotic Resistance Platform
    10:49

    Antibiotic Dereplication Using the Antibiotic Resistance Platform

    Published on: October 17, 2019

    10.7K

    Area of Science:

    • Pharmacology and Pharmaceutical Sciences
    • Infectious Diseases
    • Regulatory Science

    Background:

    • A significant unmet medical need exists for antibacterial drugs effective against resistant pathogens.
    • Developing clinical trials for narrow-spectrum antibacterial agents presents unique challenges.
    • Regulatory agencies acknowledge the need for adaptable development pathways.

    Purpose of the Study:

    • To discuss regulatory considerations for flexible development programs for antibacterial drugs.
    • To highlight the importance of these programs for addressing unmet medical needs.
    • To use a recent drug approval as a case study.

    Main Methods:

    • Review of US Food and Drug Administration (FDA) perspectives on antibacterial drug development.
    • Analysis of challenges in designing clinical trials for drugs targeting specific resistant bacteria.
    • Case study examination of the approval of sulbactam-durlobactam (XACDURO).

    Main Results:

    • Flexible development programs may be appropriate for certain antibacterial drugs.
    • The approval of XACDURO demonstrates a pathway for drugs targeting specific resistant pathogens.
    • Regulatory flexibility can facilitate the development of novel antibacterial therapies.

    Conclusions:

    • Flexible regulatory pathways are crucial for advancing antibacterial drug development.
    • Addressing resistant bacterial infections requires innovative approaches to clinical trials.
    • The FDA's recognition of these challenges supports the development of needed therapies.